Biodesix, Inc. (BDSX) News
Follow Biodesix, Inc. (BDSX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Biodesix Reports Q3 Revenue Growth and Cuts 2026 Outlook
Third-quarter revenue rose 10% year over year to $24 million, below analyst expectations. Biodesix lowered its 2026 revenue outlook to $101 million–$103 million from $108 million–$114 million.
EQUITY | Nov 06, 2026, 02:04 PM UTC
M
Biodesix Cuts Full-Year Outlook After Operational Shortcomings Hurt Growth
Biodesix cut its full-year outlook, citing operational shortcomings that hurt growth in the recent quarter. Its shares fell roughly a third in premarket trading Friday.
EARNINGS | Nov 06, 2026, 01:48 PM UTC
M
Biodesix Reports Quarterly Results for Period Ended September 30
EQUITY | Nov 05, 2026, 10:56 PM UTC
L
Biodesix 3Q 2026: Revenue $24.04M, EPS ($0.75) — 10-Q Summary
Biodesix's third-quarter revenue rose 10% year over year, while its net loss narrowed 8%. Diagnostic testing growth, driven by a 24% increase in test volume, was partly offset by lower average revenue per test; Developme
EARNINGS | Nov 05, 2026, 09:18 PM UTC
M
Biodesix Q3 Revenue Was USD 24.041 Million, Below IBES Estimate
Biodesix reported Q3 operating expenses of USD 30.153 million.
EQUITY | Nov 05, 2026, 09:04 PM UTC
L
Biodesix adds digital diagnostics to lung pipeline
Biodesix says the addition creates a growth platform combining blood and imaging biomarkers.
EQUITY | Oct 19, 2026, 10:00 AM UTC
L
Weekly Recap: HC Wainwright $38 target and advances two ctDNA MRD programs
HC Wainwright lifted its price target on Biodesix, Inc. (NASDAQ:BDSX) to $38 from $27, citing a richer diagnostics multiple and confidence in the company’s MRD testing strategy as BDSX advances tumor—informed and tumor—n
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Biodesix Price Target Raised to $38.00/Share From $27.00 by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 09:54 AM UTC
L
HC Wainwright & Co. maintains Buy rating on Biodesix, $38 price target
HC Wainwright & Co. maintained their Buy rating on Biodesix's stock with a price target of $38.00.The price target implies an upside of 30.6% from the Sep 25 close of $29.10.Key takeaways from the analyst noteStrong Grow
EQUITY | Sep 28, 2026, 09:44 AM UTC
L
Biodesix, Inc. (BDSX) Advances Tumor-Informed and Tumor-Naïve MRD Programs
Biodesix announced progress on tumor-informed and tumor-naïve MRD solutions with Bio-Rad and Thermo Fisher, to be validated with MSK and designed for deployment on partner lab platforms.Material DetailsContext by AI Anal
NEWS | Sep 24, 2026, 10:01 AM UTC
L
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertiseLOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. NASDAQ:BDSX, a lead
NEWS | Sep 24, 2026, 10:01 AM UTC
L
BDSX - Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
BDSX - Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
NEWS | Sep 24, 2026, 10:00 AM UTC
L
BDSX - Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
BDSX - Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
NEWS | Sep 14, 2026, 08:01 PM UTC
L
Biodesix leadership to present at three upcoming investor conferences
Biodesix said members of its leadership team will present in three upcoming investor conferences, including Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG…).
EQUITY | Sep 03, 2026, 10:07 AM UTC
L
BDSX - Biodesix to Participate in Upcoming Investor Conferences
BDSX - Biodesix to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 10:00 AM UTC
L
Biodesix Affirms FY2026 Sales Guidance of $108.000M-$114.000M vs $110.996M Est
Biodesix (NASDAQ: BDSX ) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.000 million-$114.000 million vs $110.996 million estimate.
EARNINGS | Aug 05, 2026, 08:02 PM UTC
L
BDSX - Biodesix Announces Second Quarter 2026 Results and Highlights
BDSX - Biodesix Announces Second Quarter 2026 Results and Highlights
EARNINGS | Aug 05, 2026, 08:01 PM UTC
M
BDSX: Roth Initiates Buy
Roth Capital initiates coverage on Biodesix with a Buy rating and a price target of $32
EQUITY | Jun 25, 2026, 11:00 AM UTC